MUC16 and familial pancreatic carcinoma: demonstrated that the ch5E6 chimeric antibody against MUC16-Cter displayed anti-tumor effects in pancreatic cancer and non-small cell lung cancer by disrupting tumor growth and signaling, inhibiting tumor cell proliferation, and its interaction with MUC16 and N-cadherin underscored its potential in targeting tumor invasiveness (154).